Rondaptivon Pegol

Intellectual property relates to key features of the company’s liquid jet injection technologySAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent and the allowance of a patent application related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,707,610 entitled, “Ingestible Device for Delivery of Therapeutic Agent to the Gastrointestinal Tract,” and has allowed U.S. Application No. 16/839,107 entitled, “Ingestible Device for Delivery of a Dispensable Substance.” Both are directed to ingestible devices for delivery of a dispensable substance to the gastrointestinal tract of a subject. “These latest patents cover key features of our unique liquid jet injection technology, including its energy source, thereby broadening the scope of protection around our BioJet platform,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “We believe we hold one of the most robust ingestible device patent portfolios, and these recent additions further strengthen our position and highlight the innovative approach we are taking to achieve category-leading bioavailability of large molecules using an oral pill,” continued Mr. Mohanty. Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 11 issued patents and 27 pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs. These patents are part of Biora’s larger corporate portfolio consisting of 73 patent families, including approximately 180 issued patents and 145 pending applications in major jurisdictions around the world, including the US, Europe, Canada, China, Japan, South Korea, Israel, Australia and Mexico. About the BioJet™ Systemic Oral Delivery Platform Biora's BioJet systemic oral therapeutics platform uses an ingestible capsule for needle-free, oral delivery of large molecules designed to achieve systemic bioavailability and replace injection for better management of chronic diseases. The BioJet platform uses an ingestible device designed to transit through the digestive system and activate in the small intestine, where liquid jets deliver drug directly into the intestinal tissue for uptake into systemic circulation. The BioJet device is approximately the size of a multivitamin and is designed to autonomously deliver a wide range of large molecules, such as proteins, peptides, and nucleic acids, in liquid formulation up to 400µL. Biora is developing multiple molecules for delivery via the BioJet platform, including BT-002, a drug-device combination consisting of a variant of adalimumab delivered via the BioJet device for the treatment of inflammatory conditions, and BT-200, which consists of a GLP-1 receptor agonist delivered via the BioJet device for the treatment of type 2 diabetes. The company is currently advancing preclinical development of both programs. Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 38 issued patents and pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs. About Biora TherapeuticsBiora Therapeutics is the biotech company that is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives. Biora is focused on development of two therapeutics platforms: the NaviCap™ targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter. Safe Harbor Statement or Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development and clinical efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future filings and initiate clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC. Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. Investor ContactChuck PadalaManaging Director, LifeSci AdvisorsIR@bioratherapeutics.com(646) 627-8390 Media Contactmedia@bioratherapeutics.com